Top
Note: Supplemental materials are not guaranteed with Rental or Used book purchases.
Purchase Benefits
Free Shipping On Orders Over $35!
Get Rewarded for Ordering Your Textbooks! Enroll Now
Customer Reviews Read Reviews
Write a Review
What is included with this book?
ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin's research has focused on cholinergic mechanisms, animal models for Alzheimer's disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer's disease.
MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.
PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.
| Preface | p. xi |
| Contributors | p. xiii |
| Basic Neuropharmacology | p. 1 |
| Soup or Sparks: The History of Drugs and Synapses | p. 3 |
| Synaptic Transmission: Intercellular Signaling | p. 39 |
| Synaptic Transmission: Intracellular Signaling | p. 59 |
| Neuronal Nicotinic Receptors: One Hundred Years of Progress | p. 107 |
| Muscarinic Acetylcholine Receptors | p. 147 |
| Norepinephrine/Epinephrine | p. 193 |
| Dopaminergic Neurotransmission | p. 221 |
| Serotonin Systems | p. 257 |
| Neuropharmacology of Histamine in Brain | p. 299 |
| Ionotropic Glutamate Receptors | p. 365 |
| Metabotropic Glutamate Receptors | p. 421 |
| Pharmacology of the GABA[subscript A] Receptor | p. 465 |
| Metabotropic GABA Receptors | p. 569 |
| Voltage-Gated Ion Chanels | p. 617 |
| Neuropeptides | p. 669 |
| Neurotransmitter Transporters | p. 705 |
| Gaseous Signaling: Nitric Oxide and Carbon Monoxide as Messenger Molecules | p. 743 |
| Mood Disorders | p. 763 |
| Neurobiology and Treatment of Depression | p. 765 |
| Neurotrophic Factors in Etiology and Treatment of Mood Disorders | p. 789 |
| Antidepressant Treatment and Hippocampal Neurogenesis: Monoamine and Stress Hypotheses of Depression Converge | p. 821 |
| Neuroendocrine Abnormalities in Women with Depression Linked to the Reproductive Cycle | p. 843 |
| Neurobiology and Pharmacotherapy of Bipolar Disorder | p. 859 |
| Index | p. 877 |
| Cumulative Index | p. 915 |
| Anxiety and Stress Disorders | p. 1 |
| Neurobiology of Anxiety | p. 3 |
| Pharmacotherapy of Anxiety | p. 59 |
| Benzodiazepines | p. 93 |
| Neuroactive Steroids in Anxiety and Stress | p. 133 |
| Emerging Anxiolytics: Corticotropin-Releasing Factor Receptor Antagonists | p. 177 |
| Neurobiology and Pharmacotherapy of Obsessive-Compulsive Disorder | p. 215 |
| Schizophrenia and Psychosis | p. 249 |
| Phenomenology and Clinical Science of Schizophrenia | p. 251 |
| Dopamine and Glutamate Hypotheses of Schizophrenia | p. 283 |
| Molecular Genetics of Schizophrenia | p. 321 |
| Postmortem Brain Studies: Focus on Susceptibility Genes in Schizophrenia | p. 343 |
| Pharmacotherapy of Schizophrenia | p. 369 |
| Atypical Antipsychotic Drugs: Mechanism of Action | p. 411 |
| Substance Abuse and Addictive Disorders | p. 449 |
| Introduction to Addictive Disorders: Implications for Pharmacotherapies | p. 451 |
| Dopaminergic and GABAergic Regulation of Alcohol-Motivated Behaviors: Novel Neuroanatomical Substrates | p. 465 |
| Nicotine | p. 535 |
| Psychostimulants | p. 567 |
| MDMA and Other "Club Drugs" | p. 613 |
| Marijuana: Pharmacology and Interaction with the Endocannabinoid System | p. 659 |
| Opiates and Addiction | p. 691 |
| Pain | p. 707 |
| Neuronal Pathways for Pain Processing | p. 709 |
| Vanilloid Receptor Pathways | p. 727 |
| Opioid Receptors | p. 745 |
| Advent of A New Generation of Antimigraine Medications | p. 757 |
| Index | p. 779 |
| Cumulative Index | p. 817 |
| Sleep and Arousal | p. 1 |
| Function and Pharmacology of Circadian Clocks | p. 3 |
| Melatonin Receptors in Central Nervous System | p. 37 |
| Narcolepsy: Neuropharmacological Aspects | p. 79 |
| Hypocretin/Orexin System | p. 125 |
| Prokineticins: New Pair of Regulatory Peptides | p. 163 |
| Sedatives and Hypnotics | p. 177 |
| Development and Developmental Disorders | p. 201 |
| Regulation of Adult Neurogenesis | p. 203 |
| Neurotrophic Factors | p. 221 |
| Neurotrophins and Their Receptors | p. 237 |
| Tourette's Syndrome and Pharmacotherapy | p. 263 |
| Neuropharmacology of Attention-Deficit/Hyperactivity Disorder | p. 291 |
| Psychopharmacology of Autism Spectrum Disorders | p. 319 |
| Neurodegenerative and Seizure Disorders | p. 345 |
| Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy | p. 347 |
| Epilepsy: Mechanisms of Drug Action and Clinical Treatment | p. 403 |
| Pharmacotherapy for Traumatic Brain Injury | p. 443 |
| Dementia and Pharmacotherapy: Memory Drugs | p. 461 |
| Pharmacotherapy and Treatment of Parkinson's Disease | p. 479 |
| Parkinson's Disease: Genetics and Pathogenesis | p. 523 |
| Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases | p. 567 |
| Neuroimmunology | p. 589 |
| Myelin Lipids and Proteins: Structure, Function, and Roles in Neurological Disorders | p. 591 |
| Pharmacology of Inflammation | p. 621 |
| Pharmacological Treatment of Multiple Sclerosis | p. 671 |
| Novel Therapies for Multiple Sclerosis | p. 683 |
| Neuropharmacology of HIV/AIDS | p. 693 |
| Eating and Metabolic Disorders | p. 731 |
| Leptin: A Metabolic Perspective | p. 733 |
| Ghrelin: Structural and Functional Properties | p. 765 |
| Mechanisms Controlling Adipose Tissue Metabolism by the Sympathetic Nervous System: Anatomical and Molecular Aspects | p. 785 |
| Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives | p. 815 |
| Index | p. 845 |
| Cumulative Index | p. 881 |
| Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Need Help? Copyright © 1999-2024